FDA Generic Office Wants “Controlled Correspondence” Under Control
Executive Summary
FDA's Office of Generic Drugs is offering suggestions to industry to help reduce the amount of "controlled correspondence" the agency receives
You may also be interested in...
FDA ANDA Full Approvals Down In FY 2003, Total Applications Increase
The number of full generic drug approvals dropped slightly in fiscal 2003 to 284, compared to 296 in fiscal 2002
FDA ANDA Full Approvals Down In FY 2003, Total Applications Increase
The number of full generic drug approvals dropped slightly in fiscal 2003 to 284, compared to 296 in fiscal 2002
FDA’s Generic Priorities: McClellan Lays Out Ambitious Agenda At GPhA
FDA is developing a process to flag NDAs that may pose difficulties for future generic development, Commissioner Mark McClellan, MD/PhD, said at the Generic Pharmaceutical Association annual meeting in Rio Grande, Puerto Rico Jan. 29